Ono Pharmaceutical: Pipeline, Products, Performance, Potential

Date: April 22, 2011
Pages: 60
Price:
US$ 1,040.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: OD056D12DEAEN
Leaflet:

Download PDF Leaflet

Ono Pharmaceutical: Pipeline, Products, Performance, Potential
Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Snapshot Ono Pharmaceuticals - Is a pharma merger required?

Fiscal 2009 was another difficult period for Ono. Historically, the company markets products for niche indications, ensuring low competition and steady sales. However, recent governmental price cuts and the implementation of various healthcare cost containment policies have hit the company hard, leading to declines in revenue and income. Ono is not the only Japanese company to be impacted by these factors, several of its competitors have entered into mergers to strengthen their position. In recent years, five major mergers have occurred in Japan to form Dainippon Sumitomo Pharma (Dainippon and Sumitomo Pharmaceutical), Astellas Pharma (Yamanouchi and Fujisawa), Mitsubishi-Tanabe Pharma (Mitsubishi Pharma and Tanabe), Daiichi Sankyo (Daiichi and Sankyo Pharmaceutical) and most recently, Kyowa Hakko Kirin (Kyowa Hakko and Kirin Brewery). Ono has not announced any merger intentions, which places the company in a vulnerable position.

If Ono is to emerge from this difficult period, the company will have to rapidly overhaul its product portfolio to market products with forecasted long-term growth. To this end, Ono established its Strategic Alliance division in 2007. This business segment is actively seeking collaborations around the globe in order to expand the pipeline through licensing agreements and bring candidate compounds to market more rapidly through research alliances. Agreements with Merck & Co, Novartis and Astellas have seen the pipeline bolstered by additions of Glactiv, Rivastach Patch and Recalbon, which are forecast to make strong contributions to company revenue. Drug development in Japan is focused on obtaining early approval for late-stage compounds, leveraged by results from multinational clinical trials and other international studies. Ono is also focused on acquiring commercialisation rights to new drug candidates. Gaining new drug approvals in Europe and the US, particularly in areas of unmet medical need, remains a key focus for Ono.

As one of the smaller players in the Japanese market, and certainly globally, a portfolio overhaul may not be sufficient to maintain Ono's centuries old business. Ono should consider combining its aggressive licensing and collaborative strategy with a major pharmaceutical merger if it is to return to sales growth.

But what's in the pipeline? For the full story on Ono Pharmaceutical's challenges and opportunities order this important strategic analysis today

This new strategic report provides a detailed analysis of Ono Pharmaceutical's competitive position and prospect for the futures. Using primary source information complemented by original 7-year product forecasts and competitive analysis, the report gives a complete and compelling oversight of the company, its products, pipeline and prospects.

Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.
Latest Results

EXECUTIVE SUMMARY

Introduction
Current Financial Position
  Company Performance
  Geographic Segment Performance
Company Strategy
  R&D Strategy
  Key Agreements
  Employees
Product Performance Forecasts
Pipeline Analysis
  Discontinued R&D
Conclusions/Outlook

THERAPEUTIC AREA FOCUS

R&D PIPELINE

CARDIOVASCULAR

Marketed Products
  Onoact
  Opalmon
R&D Projects

RESPIRATORY

Marketed Products
  Onon
R&D Projects

INFLAMMATION

Marketed Products
  Foipan
  Recalbon
R&D Projects
  ONO-5334

CNS

  Kinedak
R&D Projects
  ONO-4641
  Remimazolam
  Rivastach

METABOLISM

Marketed Products
  Glactiv
R&D Projects

OTHERS

Marketed Products
  Emend
R&D Projects
  Asimadoline
  Carfilzomib
  ONO-7643
  ONO-8539

APPENDIX 1 - FINANCIAL PERFORMANCE

Full Year Results 2009

APPENDIX 3 - KEY AGREEMENTS

Ansaris
Array BioPharma Inc
BioFocus DPI Plc
BioSeek
Dainippon Sumitomo Pharma
Dong-A Pharmaceuticals Co Ltd
Evotec
GlaxoSmithKline
Kyowa Hakko Kirin
Locus Pharmaceuticals Inc
Medarex Inc
Merck & Co
Nissan Chemical Industries Ltd
Novartis
PAION AG
Progenics Pharmaceuticals
Recordati
Sapphire Therapeutics Inc
Santen Pharmaceutical Co Ltd
Tioga Pharmaceuticals
UCB
Xention

APPENDIX 4 - INFRASTRUCTURE

Research and Development Facilities
Manufacturing Facilities

APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES

Subsidiaries
Joint Ventures

APPENDIX 6 - PRODUCT INDEX

LIST OF TABLES

Principal Operating Results
Recent Product Approvals
Opalmon/ProRenal Sales by Company (2008-2016)

LIST OF CHARTS

Sales by Geographic Area, 2009
Sales of Top Ten Products (2008-2016)
Top Selling Products, 2009
Opalmon/ProRenal Sales (2008-2016)
Onon Sales (2008-2016)
Recalbon Sales (2009-2016)
Glactiv Sales (2009-2016)
Emend Sales (2009-2017)
Staybla Sales (2008-2016)
Carfilzomib Sales (2013-2016)
Sales, Costs and Operating Income
Profitability and Research Ratios
R&D Expenditure and Capital Expenditure
Current Assets, Liabilities and Ratio
Assets, Cash and Liquidity
Employees and Productivity
Skip to top


Otsuka: Pipeline, Products, Performance, Potential US$ 1,040.00 Apr, 2008 · 80 pages
Wyeth: Pipeline, Products, Performance, Potential US$ 1,040.00 Mar, 2008 · 152 pages
Allergan: Pipeline, Products, Performance, Potential US$ 1,040.00 Apr, 2009 · 80 pages
Biogen Idec: Pipeline, Products, Performance, Potential US$ 1,040.00 Jan, 2010 · 86 pages
Chugai: Pipeline, Products, Performance, Potential US$ 1,040.00 Oct, 2009 · 80 pages

Ask Your Question

Ono Pharmaceutical: Pipeline, Products, Performance, Potential
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: